PNOC029 is a Phase II, open-label study of tovorafenib for patients aged 1 to 39 years with newly diagnosed or recurrent craniopharyngioma. Participants receive a pre-operative dose of tovorafenib before standard-of-care biopsy or resection. Those with residual or measurable disease may continue once-weekly oral tovorafenib in 28-day cycles for up to 24 months, unless there is disease progression or unacceptable toxicity. The primary aim is to assess 12-month progression-free survival and maintenance of physical quality of life compared with historical controls. Secondary assessments include safety, radiographic response, visual outcomes, neuroendocrine outcomes, and longer-term quality of life.